Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

Yang, Lele; Zhu, Wei; Zhang, Xiaobo; Zhou, Xin; Wu, Wei; Shen, Tao

doi:10.1016/j.phymed.2023.154716

Cited by 7 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some people may experience minor GI side effects from BBR [ 89 ]. In a recent meta-analysis study of 44 RCTs involving 4606 patients with cardiovascular diseases, no serious adverse reaction was reported with BBR supplementation [ 90 ]. The safety and tolerability of CUR is well established in humans.…”

Section: Discussionmentioning

confidence: 99%

The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study

Wade,

Pascual-Figal,

Rabbani

et al. 2024

Nutrients

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a prevalent chronic functional gastrointestinal disorder, characterised by recurrent abdominal discomfort and altered bowel movements. IBS cause a significantly negative impact on quality of life (QoL). Growing pharmacological evidence suggests that berberine (BBR) and curcumin (CUR) may mitigate IBS symptoms through multiple complementary synergistic mechanisms, resulting in the attenuation of intestinal inflammation and regulation of bowel motility and gut functions. In the present observational study conducted under real-life routine clinical practice settings, 146 patients diagnosed with IBS were enrolled by general practitioner clinics and pharmacies in Belgium. For the first time, this study assessed the potential synergistic pharmacological effect of a combined oral BBR/CUR supplement (Enterofytol® PLUS, containing 200 mg BBR and 49 mg CUR) (two tablets daily for 2 months), serving as complementary therapy in the management of IBS. Following the 2-month supplementation, significant improvements were observed in the patients’ IBS severity index (IBSSI) (47.5%) and all the primary IBS symptoms, such as abdominal discomfort (47.2%), distension (48.0%), intestinal transit (46.8%), and QoL (48.1%) (all p < 0.0001). The improvement in the patients’ IBSSI was independent of age, sex, and IBS sub-types. The patients’ weekly maximum stool passage frequency decreased significantly (p < 0.0001), and the stool status normalized (p < 0.0001). The patients’ need for concomitant conventional IBS treatment decreased notably: antispasmodics by 64.0% and antidiarrhoeals by 64.6%. Minor adverse effects were reported by a small proportion (7.1%) of patients, mostly gastrointestinal. The majority (93.1%) experienced symptom improvement or resolution, with a high satisfaction rate (82.6%) and willingness to continue the supplementation (79.0%). These findings support the potential synergistic pharmacological role of BBR and CUR in IBS, and their co-supplementation may alleviate IBS symptoms and improve QoL.

show abstract

Section: Discussionmentioning

confidence: 99%

The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study

Wade,

Pascual-Figal,

Rabbani

et al. 2024

Nutrients

View full text Add to dashboard Cite

show abstract

“…Berberine, in addition to having many experimental studies to support its positive action on glucose metabolism and IR/Hyperins, also has many clinical studies that support its role in cardiovascular prevention. A review and meta-analysis of randomized controlled trials on berberine has highlighted how it can be a valid alternative, without causing serious adverse reactions, to drugs currently used for cardiovascular prevention ( 66 ). In a randomized, placebo -controlled study lasting 4 months, 59 patients with metabolic syndrome were treated with a combination of nutraceuticals, containing berberine 500 mg, or placebo.…”

Section: Tratment Of Ir/hyperinsmentioning

confidence: 99%

Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated

Fazio,

Mercurio,

Tibullo

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Cardiovascular mortality is still excessively high, despite the considerable progress made in the prevention and treatment of cardiovascular diseases. Although many cardiovascular risk factors (such as arterial hypertension, hypercholesterolemia, diabetes, etc.), identified in the general population, are being promptly treated, to date little consideration is given to a cardiovascular risk factor which we believe has largely demonstrated in the scientific literature of the last three decades that, if neglected, can produce a series of relevant negative effects on the cardiovascular system: insulin resistance (IR)/hyperinsulinemia (Hyperins). This risk factor is still not sufficently sought in the general population and, consequently, is not treated promptly, as it should be, to avoid its negative impact on the cardiovascular system. IR's prevalence is constantly growing worldwide, and it is estimated to have reached a prevalence of 51% of the general population in developed and developing countries, and Hyperins is a constant and strong feature of IR. This article aims to stimulate the scientific community towards IR/Hyperins as relevant cardiovascular risk factor, since it is still neglected. The scientific literature analyzed and used to for this article was found on PubMed, Scopus, Science Direct, etc, using the following keywords: insulin, insulin signaling, insulin resistance, hyperinsulinemia, cardiovascular risk factors, cardiovascular system, cardiovascular diseases. We selected studies that explored the association between IR/Hyperins and the cardiovascular system, and those that discussed the possibilities of screening and treatment of IR/Hyperins.

show abstract

“…Meanwhile, the use of nutraceuticals containing BBR has gradually expanded owing to their better lipid-lowering effects, and no adverse events have been reported during their administration ( Riccioni et al, 2018 ). Statins are routinely used in the treatment of hyperlipidemia, and the incidence of adverse events is not statistically significant when comparing BBR treatment to treatment with statin ( Yang et al, 2023 ).…”

Section: Safety and Tolerability Of Bbr In Lipid Metabolic Diseasesmentioning

confidence: 99%

Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review

Cai,

Yang,

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Lipid-lowering therapy is an important tool for the treatment of lipid metabolic diseases, which are increasing in prevalence. However, the failure of conventional lipid-lowering drugs to achieve the desired efficacy in some patients, and the side-effects of these drug regimens, highlight the urgent need for novel lipid-lowering drugs. The liver and intestine are important in the production and removal of endogenous and exogenous lipids, respectively, and have an important impact on circulating lipid levels. Elevated circulating lipids predisposes an individual to lipid deposition in the vascular wall, affecting vascular function. Berberine (BBR) modulates liver lipid production and clearance by regulating cellular targets such as cluster of differentiation 36 (CD36), acetyl-CoA carboxylase (ACC), microsomal triglyceride transfer protein (MTTP), scavenger receptor class B type 1 (SR-BI), low-density lipoprotein receptor (LDLR), and ATP-binding cassette transporter A1 (ABCA1). It influences intestinal lipid synthesis and metabolism by modulating gut microbiota composition and metabolism. Finally, BBR maintains vascular function by targeting proteins such as endothelial nitric oxide synthase (eNOS) and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1). This paper elucidates and summarizes the pharmacological mechanisms of berberine in lipid metabolic diseases from a multi-organ (liver, intestine, and vascular system) and multi-target perspective.

show abstract

Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

Cited by 7 publications

References 47 publications

The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study

The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study

Insulin resistance/hyperinsulinemia: an important cardiovascular risk factor that has long been underestimated

Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review

Contact Info

Product

Resources

About